EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease

Gina Sado, Katrin Kemp Gudmundsdottir, Carl Bonander, Mattias Ekström, Johan Engdahl, Emma Svennberg

IJC Heart & Vasculature · 2024-12 · 55 · 101549

DOI: 10.1016/j.ijcha.2024.101549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJC Heart & Vasculature, 2024-12. Verfasst von Gina Sado und 5 weiteren Autor:innen. Beteiligte Einrichtung: Karolinska Institutet, Department of Medicine, Karolinska University Hospital Huddinge, Sweden. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hjärt-Lungfonden, Vetenskapsrådet, Roche Diagnostics Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atrial fibrillation (AF) screening should be considered in elderly patients with high risk of stroke, which include individuals with hypertension. The biomarker N-terminal prohormone of brain natriuretic peptide (NT-proBNP) can predict incident AF and is increased in hypertensive individuals. The aim of this study is to investigate the incidence of screening-detected AF in elderly individuals in relation to NT-proBNP and hypertension.

Methods

STROKESTOP II is a randomized controlled trial in which 75/76-years-old individuals were invited to a screening study for AF using NT-proBNP as a discriminator of high risk. In this sub-study, a prior hypertension diagnosis was self-reported by participants and measured blood pressure was stratified into hypertension-grades. Individuals with both increased blood pressure (≥140 mmHg) and NT-proBNP ≥ 125 ng/L were defined as a high-risk group. The lowest risk-group was defined as normotensive participants with NT-proBNP 125 ng/l and SBP ≥ 140 mmHg, (AF = 65/1741, 3.7 %) compared to the low-risk group (AF = 2/1444, 0.1 %), p < 0.001.

Conclusion

NT-proBNP is elevated in elderly patients with hypertension and increases with grades of hypertensive disease. NT-proBNP is a strong predictor of AF regardless of high blood pressure, and the risk for screening-detected AF is very low in participants with normal blood pressure and low NT-proBNP. A combination of blood pressure and NT-proBNP could identify suitable participants for AF screening.

Schlagwörter

Stichwörter der Autor:innen

Atrial fibrillationBlood pressureHypertensionHypertension gradesMass screeningNT-proBNP

Autor:innen und Institutionen

  • Karolinska Institutet, Department of Medicine, Karolinska University Hospital Huddinge, Sweden.
  • Department of Cardiology, Danderyd University Hospital, Stockholm, Sweden.
  • Karolinska Institutet, Department of Clinical Sciences - Danderyd University Hospital, Sweden.
  • School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Sweden.

Förderung

  • Hjärt-Lungfonden
  • Vetenskapsrådet
  • Roche Diagnostics Corporation
  • Stockholms Läns Landsting
  • Center for Innovative Medicine

Zitieren

APA

Sado, G., Kemp Gudmundsdottir, K., Bonander, C., Ekström, M., Engdahl, J., & Svennberg, E. (2024). The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease. IJC Heart & Vasculature, 55, 101549. https://doi.org/10.1016/j.ijcha.2024.101549

Vancouver

Sado G, Kemp Gudmundsdottir K, Bonander C, Ekström M, Engdahl J, Svennberg E. The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease. IJC Heart & Vasculature. 2024;55:101549. doi:10.1016/j.ijcha.2024.101549

BibTeX
@article{Sado2024,
  author = {Sado, Gina and Kemp Gudmundsdottir, Katrin and Bonander, Carl and Ekström, Mattias and Engdahl, Johan and Svennberg, Emma},
  title = {The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease},
  journal = {IJC Heart & Vasculature},
  year = {2024},
  volume = {55},
  pages = {101549},
  doi = {10.1016/j.ijcha.2024.101549}
}
Kostenlos starten →